{"id":"sitagliptin-phosphate-metformin-hydrochloride-fdc","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a DPP-4 inhibitor that prevents the breakdown of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby increasing insulin secretion in response to meals and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose production and improves peripheral insulin sensitivity. Together, they provide complementary glucose-lowering effects in type 2 diabetes.","oneSentence":"This combination drug inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:18.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07452913","phase":"PHASE4","title":"Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":172},{"nctId":"NCT06124495","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-13","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124547","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-16","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT06124560","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-10-28","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124573","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-11-07","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT03927170","phase":"PHASE1","title":"Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2019-05-02","conditions":"Healthy","enrollment":25},{"nctId":"NCT00961857","phase":"PHASE1","title":"A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12-01","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT03851341","phase":"PHASE1","title":"Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2019-01-02","conditions":"Healthy","enrollment":30},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT01702298","phase":"PHASE3","title":"A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":42},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00929201","phase":"PHASE1","title":"Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":61},{"nctId":"NCT01093794","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT00961480","phase":"PHASE1","title":"A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Type 2 Diabetes","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Janumet®"],"phase":"marketed","status":"active","brandName":"Sitagliptin phosphate/metformin hydrochloride FDC","genericName":"Sitagliptin phosphate/metformin hydrochloride FDC","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}